Why is Midostaurin so expensive?

Midostaurin is a multi-target tyrosine kinase inhibitor that was first developed by Novartis. Its most representative indications are FLT3 mutation-positive acute myeloid leukemia (AML) and advanced systemic mastocytosis. In the treatment of acute myeloid leukemia, midostaurin is often used in combination with standard chemotherapy regimens to delay disease progression and improve remission rates; in systemic mast cell diseases, midostaurin exerts its efficacy by inhibiting the signaling pathway of the KIT D816V mutation.

The reasons for the higher price mainly involve the following aspects. First of all, midostaurin, as an original drug, has high research and development costs. From basic research to clinical trials to multi-country marketing approval, pharmaceutical companies spend huge amounts of money, and these costs are inevitably reflected in drug pricing. Secondly, because the indication population is relatively limited, especially in the field of rare diseases, companies need to balance the contradiction between R&D and market size by increasing unit prices. Third, midostaurin is not yet on the market in China, nor is it included in the medical insurance catalog, which means there is no price reduction process through price negotiation. Therefore, if patients obtain the original drug through formal channels, they can only bear the higher international market price.

Currently in overseas markets, the common specifications of midostaurin are25mg, 112 pills per box. Its price varies significantly depending on the region, and usually fluctuates between RMB 10,000 and RMB 70,000, mainly affected by exchange rates and distribution channels. In contrast, the generic drugs launched in countries such as India have significantly reduced the cost of medication. For example, the version produced by BDR Pharmaceuticals costs about 3,000 yuan per box and has the same ingredients as the original drugs, providing patients with a more accessible alternative. However, the quality standards and clinical substitutability of generic drugs still need to be strictly supervised, so patients must take into account doctor's advice when choosing and avoid blind substitution simply because of price.

Reference materials:https://go.drugbank.com/drugs/DB06595